Ratings MedAdvisor Limited

Equities

MDR

AU000000MDR6

Market Closed - Australian S.E. Other stock markets 02:10:46 2024-05-10 am EDT			5-day change	1st Jan Change
0.33 ^AUD	0.00%		+6.45%	+53.49%

Apr. 24	MedAdvisor Operating Revenue Rises 42% to AU$24.2 Million in March Quarter	MT
Apr. 23	MedAdvisor's Gross Profit Climbs 48.5% in Fiscal Q3, Revenue Rises 42.4%	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past four months, analysts' average price target has been revised upwards significantly.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The company is highly valued given the cash flows generated by its activity.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
MEDADVISOR LIMITED	+53.49%	120M		-
VEEVA SYSTEMS INC.	+5.85%	32.93B		C
PRO MEDICUS LIMITED	+20.16%	7.94B		C-
SECTRA AB	+30.81%	4.19B		B-
EVOLENT HEALTH, INC.	-25.95%	2.8B		C-
OMNICELL, INC.	-19.96%	1.38B		B
LUNIT INC.	-31.87%	1.17B		-
SIMULATIONS PLUS, INC.	+8.02%	966M		C
B-SOFT CO.,LTD.	-35.73%	900M		-
VERADIGM INC.	-25.74%	839M	-	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes